SC
ALNY icon

SouthState Corp’s Alnylam Pharmaceuticals ALNY Stock Holding History

SouthState Corp’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.31K Sell
11
-2
-15% -$603 ﹤0.01% 861
2026
Q1 		$4.3K Sell
13
-1
-7% -$340 ﹤0.01% 778
2025
Q4 		$5.57K Sell
14
-6
-30% -$2.65K ﹤0.01% 783
2025
Q3 		$9.12K Sell
20
-6
-23% -$2.44K ﹤0.01% 676
2025
Q2 		$8.48K Buy
26
+5
+24% +$1.38K ﹤0.01% 813
2025
Q1 		$5.67K Buy
+21
New +$5.4K ﹤0.01% 964
2024
Q2 		– Sell
-6
Closed -$897 – 641
2024
Q1 		$897 Buy
+6
New +$1K ﹤0.01% 651

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SouthState Corp's ALNY Position: Q2 2026 in Review

SouthState Corp reduced its Alnylam Pharmaceuticals (ALNY) stake by 15% in Q2 2026, selling an estimated $603 and leaving 11 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #861.

SouthState Corp first reported a position in ALNY in Q1 2024 and has held it in 7 quarters since. The position peaked at $9.12K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • SouthState Corp held 11 shares of Alnylam Pharmaceuticals worth $3.31K as of Q2 2026.
  • SouthState Corp sold 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
  • Alnylam Pharmaceuticals made up ﹤0.01% of SouthState Corp's portfolio in Q2 2026, its #861 holding.
  • SouthState Corp first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • SouthState Corp's Alnylam Pharmaceuticals position peaked at $9.12K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on SouthState Corp's 13F filing for Q2 2026, filed 6 Aug 2026.